- Conditions
- Advanced Cancer
- Interventions
- Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 57
- States / cities
- Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,581
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- larotaxel (XRP9881), gemcitabine, cisplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 52
- States / cities
- Anchorage, Alaska • Berkeley, California • Burbank, California + 46 more
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
- Interventions
- Palbociclib Oral Product, TAS-116
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor
- Interventions
- APR-246 (eprenetapopt) + Pembrolizumab
- Drug
- Lead sponsor
- Aprea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
- Conditions
- Bladder Outlet Obstruction
- Interventions
- Toviaz (Fesoterodine)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 40 Years to 99 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Cancer
- Interventions
- P3BC
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Seattle, Washington
- Conditions
- Bladder Cancer
- Interventions
- LifeScience Technologies application
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Pelvic Floor Disorders, Interstitial Cystitis, Urinary Incontinence
- Interventions
- ACE questionnaire
- Other
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 356 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 21
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 11 more
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Procedure · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 83
- States / cities
- Littleton, Colorado • Bloomington, Illinois • Canton, Illinois + 64 more
- Conditions
- Carcinoma, Transitional Cell
- Interventions
- Tesetaxel
- Drug
- Lead sponsor
- Genta Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
- Interventions
- Carboplatin, Cisplatin, Palbociclib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Overactive Bladder, Lower Urinary Tract Symptoms
- Interventions
- Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy
- Behavioral · Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • San Antonio, Texas
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome
- Interventions
- Lidocaine, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Interventions
- eCoin Tibial Nerve Stimulation
- Device
- Lead sponsor
- Valencia Technologies Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Waterloo, Iowa • Greensboro, North Carolina + 1 more
- Conditions
- Urge Incontinence, Overactive Bladder
- Interventions
- Transcutaneous Electrical Nerve Stimulation
- Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Urinary Tract Infections, Bladder Cancer
- Interventions
- Vikor Scientific Urine-IDTM
- Diagnostic Test
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 448
- States / cities
- Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
- Conditions
- Overactive Bladder
- Interventions
- Toviaz, Premarin, Placebo cream
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 30 Years to 100 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
- Drug · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
- Conditions
- Interstitial Cystitis
- Interventions
- H&P; ECG; Blood tests; voiding diary; Cystoscopy
- Procedure
- Lead sponsor
- ICOS Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 24
- States / cities
- Anchorage, Alaska • Glendora, California • La Mesa, California + 20 more
- Conditions
- Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Interventions
- Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
- Dietary Supplement · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more
- Conditions
- Cystitis, Interstitial, Ulcer
- Interventions
- LiRIS®, LiRIS Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Murrieta, California • Vacaville, California • Farmington, Connecticut + 14 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- solifenacin succinate
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 198
- States / cities
- Bay Minette, Alabama • Birmingham, Alabama • Decatur, Alabama + 171 more